|  | 
| CD205, a target antigen for a novel antibody drug conjugate (ADC): Evaluation of antigen expression on non-Hodgkin lymphoma (NHL). | 
|  | 
|  | 
| Research Funding - Menarini (Inst) | 
|  | 
|  | 
| Research Funding - Menarini (Inst) | 
|  | 
|  | 
| Honoraria - CTI; Gilead Sciences; Janssen-Cilag; Menarini; Mundipharma; Roche; SERVIER; Takeda; Teva | 
| Consulting or Advisory Role - CTI; Gilead Sciences; Janssen-Cilag; Mundipharma; SERVIER | 
| Research Funding - Menarini (Inst) | 
|  | 
|  | 
| No Relationships to Disclose | 
|  | 
|  | 
| Employment - Oxford BioTherapeutics | 
| Research Funding - Oxford BioTherapeutics | 
| Travel, Accommodations, Expenses - Oxford BioTherapeutics | 
|  | 
|  | 
| Employment - Oxford BioTherapeutics | 
| Stock and Other Ownership Interests  - Bristol-Myers Squibb; Caladrius Biosciences; CytomX Therapeutics; Ensigna Biosystems; Genomic Health; Gilead Sciences; Sanofi | 
| Research Funding - Oxford BioTherapeutics | 
| Travel, Accommodations, Expenses - Leica Biosystems; Oxford BioTherapeutics | 
|  | 
|  | 
| No Relationships to Disclose | 
|  | 
|  | 
| No Relationships to Disclose | 
|  | 
|  | 
|  | 
|  | 
|  | 
|  | 
|  | 
|  | 
| Employment - Oxford BioTherapeutics | 
| Research Funding - Oxford BioTherapeutics | 
|  | 
|  | 
| No Relationships to Disclose | 
|  | 
|  | 
|  | 
|  | 
|  | 
|  | 
| No Relationships to Disclose | 
|  | 
| Andrea Ugo Enrico  Pellacani | 
|  | 
|  | 
| Stock and Other Ownership Interests  - Amgen | 
|  | 
|  | 
|  | 
|  |